

# Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

## Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com

# **PRODUCT** INFORMATION



BMS 582949

Item No. 22892

CAS Registry No.:	623152-17-0
Formal Name:	4-[[5-[(cyclopropylamino)carbonyl]-
	2-methylphenyl]amino]-5-methyl-N-
	propyl-pyrrolo[2,1-f][1,2,4]triazine-6-
	carboxamide /
MF:	$C_{22}H_{26}N_6O_2$
FW:	406.5
Purity:	≥98%
UV/Vis.:	$\lambda_{max}$ : 253 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.	

Laboratory Procedures

BMS 582949 is supplied as a crystalline solid. A stock solution may be made by dissolving the BMS 582949 in the solvent of choice, which should be purged with an inert gas. BMS 582949 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of BMS 582949 in these solvents is approximately 1, 15, and 30 mg/ml, respectively.

BMS 582949 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BMS 582949 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. BMS 582949 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

#### Description

BMS 582949 is an orally bioavailable p38 $\alpha$  MAP kinase inhibitor (IC<sub>50</sub> = 13 nM in an enzyme assay).<sup>1</sup> It also inhibits TNF- $\alpha$  production in human peripheral blood mononuclear cells (PBMC; IC<sub>50</sub> = 50 nM). When administered at a dose of 5 mg/kg in mice, it decreases LPS-induced TNF- $\alpha$ production up to 89% compared to vehicle. BMS 582949 reduces paw swelling in a rat adjuvant arthritis model when administered once per day (1, 10, or 100 mg/kg) or twice per day (1 or 5 mg/kg).

#### Reference

1. Liu, C., Lin, J., Wrobleski, S.T., et al. Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases. J. Med. Chem. 53(18), 6629-6639 (2010).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFFTY DATA

SAFETY DATA This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/19/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM